PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 21, 2026Scandinavian Journal of Immunology0 citationsOpen Access

Combined Immunodeficiency Associated With MAP2K1 p. Tyr130His Variant in Cardiofaciocutaneous Syndrome: A Case Report With Literature‐Based Phenotypic Comparison

View Full Paper
JHJulia HornATAslı Berivan TopçakYTYelda Türkmenoğlu

Key Points

  • To describe a case of combined immunodeficiency associated with the MAP2K1 p.Tyr130His variant in a patient with cardiofaciocutaneous syndrome.
  • Clinical presentation including recurrent infections and growth failure in a 4-month-old female
  • Immunologic evaluations showing hypogammaglobulinemia and low T cell subsets
  • Genetic testing confirming the MAP2K1 p.Tyr130His variant
  • Treatment with intravenous immunoglobulin and prophylaxis
  • The patient exhibited recurrent infections and growth failure throughout her early life
  • Immunologic workup revealed significantly low levels of T cells and insufficient vaccine responses
  • Post-treatment, the patient showed clinical improvement, especially in immune function

Abstract

ABSTRACT Cardiofaciocutaneous syndrome (CFCS) is a RASopathy involving craniofacial, cardiac, cutaneous, and neurologic features. MAP2K1 mutations, particularly in the kinase domain, are linked to CFCS type 3. Immune dysfunction has not previously been reported with the p.Tyr130His variant. To describe the case of combined immunodeficiency (CID) associated with the MAP2K1 p.Tyr130His variant. A 4‐month‐old female with CFCS presented with recurrent infections, growth failure, and ectodermal findings. Immunologic workup revealed hypogammaglobulinemia, low T cell subsets, and absent vaccine responses. Genetic analysis identified the MAP2K1 p.Tyr130His variant. She was started on intravenous immunoglobulin and prophylaxis, with clinical improvement. We describe a case of CID associated with the MAP2K1 p.Tyr130His variant adding to the growing evidence of immune dysregulation in CFCS.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Horn et al. (2026) studied this question.

synapsesocial.com/papers/69994bef873532290d02000chttps://doi.org/10.1111/sji.70101
Ask AI
Helpful
Bookmark
Share
View Full Paper